http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108785273-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108785273-B |
| titleOfInvention | Entecavir capsule pharmaceutical composition and preparation method thereof |
| abstract | The invention provides an entecavir capsule pharmaceutical composition and a preparation method thereof. The composition comprises micronized entecavir, micronized magnesium stearate, pregelatinized starch and microcrystalline cellulose, wherein the particle size distribution characteristics of the micronized entecavir and the micronized magnesium stearate are D 90 Less than or equal to 30 mu m, and is prepared by mixing entecavir and magnesium stearate and then carrying out co-micronization. The pharmaceutical composition has the advantages of good stability, high dissolution rate, high bioavailability, simple formula and preparation process, and suitability for industrial production. |
| priorityDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.